Case Study For Alzheimer’s Disease Assignment Paper

Case Study For Alzheimer’s Disease Assignment Paper

Need Help Writing an Essay?

Tell us about your assignment and we will find the best writer for your paper

Write My Essay For Me

The assigned patient case study is on Mr. Akkad, a 76-year-old Iranian man, whose son brought him in because of his peculiar behavior. Prior to this evaluation, Mr. Akkad’s family doctor ruled out any organic causes for Mr. Akkad’s behavior. Mr. Akkad disclosed personality changes, a lack of interest in religious pursuits, and memory issues during the clinical interview. His Mini-Mental State Test result of 18 out of 30 indicated mild dementia. Major neurocognitive disorder resulting from Alzheimer’s disease was the identified condition (presumptive)Case Study For Alzheimer’s Disease Assignment Paper.

ORDER A PLAGIARISM-FREE PAPER HERE

The client would be required to see the clinic again in four weeks, which was the first decision. The client’s disinhibited actions persisted, and the son reported no change with the medicine at the follow-up. Moreover, Mr. Akkad performed poorly on the Mini-Mental State Test, scoring 18 out of 30; his main areas of weakness were orientation, registration, attention and calculation, and recall. Exelon’s dosage was increased to 6 mg orally BID at the second decision point (Nguyen et al., 2021)Case Study For Alzheimer’s Disease Assignment Paper. The client’s habits remained unchanged, and the son claimed that he had to stop giving his father the prescription because of nausea and diarrhea. The third choice was to reduce Exelon’s dosage to 3 mg orally, BID.

It is evident from the patient case study judgments that they were backed by the available evidence-based literature. For instance, the first choice to administer Exelon was made based on the proof that individuals with Alzheimer’s disease can experience symptomatic alleviation from acetylcholinesterase inhibitors (Ray et al., 2020). The evidence did not, however, support the decision to increase the Exelon dose, as rapid uptitration can have unfavorable effects, including gastrointestinal issues. Evidence was used to support the third decision to reduce the Exelon dosage because doing so is advised when side effects are present (Ruangritchankul et al., 2021)Case Study For Alzheimer’s Disease Assignment Paper.

The choices chosen were intended to enhance the patient’s quality of life as well as his cognitive and behavioral problems. There is evidence that acetylcholinesterase inhibitors can help Alzheimer’s patients with behavioral symptoms including agitation and apathy as well as cognitive function (Cloak & Al Khalili, 2019). The patient’s quality of life can also be enhanced by measures including psychological therapy and caregiver assistance.
Hence, it was decided that in order to attain the stated goals, the patient would begin therapy with an acetylcholinesterase inhibitor and receive psychological therapies as well as caregiver support. The patient and his family received information about the plan as well as the necessary training and tools. To keep track of the patient’s progress and modify the treatment strategy as necessary, follow-up sessions were set up Case Study For Alzheimer’s Disease Assignment Paper.

The second choice’s projected result and actual result were at odds with one another. The patient’s conduct and intellect were supposed to improve, but instead the patient experienced vomiting and diarrhea, which forced the doctor to stop the prescription. This emphasizes how critical it is to keep an eye out for side effects in patients, especially while increasing pharmaceutical dosages.

In conclusion, Mr. Akkad’s patient case study highlighted a difficulty in the treatment of Alzheimer’s disease. Exelon was started, the dose was increased, and the dose was decreased due to side effects based on evidence. The decisions made were backed by the literature and attempted to enhance the patient’s cognitive and behavioral symptoms as well as their quality of life, even though the desired results were not always reached. In order to manage Alzheimer’s disease effectively, it is essential to closely monitor the patient for any negative side effects Case Study For Alzheimer’s Disease Assignment Paper.

References

Cloak, N., & Al Khalili, Y. (2019). Behavioral and psychological symptoms in dementia.

https://europepmc.org/article/nbk/nbk551552

Nguyen, K., Hoffman, H., Chakkamparambil, B., & Grossberg, G. T. (2021). Evaluation of rivastigmine in Alzheimer’s disease. Neurodegenerative Disease Management, 11(1), 35-48.

ORDER NOW

https://www.futuremedicine.com/doi/abs/10.2217/nmt-2020-0052

Ray, B., Maloney, B., Sambamurti, K., Karnati, H. K., Nelson, P. T., Greig, N. H., & Lahiri, D. K. (2020). Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease. Translational Psychiatry, 10(1), 47.

https://www.nature.com/articles/s41398-020-0709-x

Ruangritchankul, S., Chantharit, P., Srisuma, S., & Gray, L. C. (2021). Adverse drug reactions of acetylcholinesterase inhibitors in older people living with dementia: a comprehensive literature review. Therapeutics and Clinical Risk Management, 927-949. https://www.tandfonline.com/doi/abs/10.2147/TCRM.S323387 Case Study For Alzheimer’s Disease Assignment Paper